VeroScience LLC emerged from stealth mode Wednesday to report that its lead product Cycloset gained FDA approval, making it the first dopamine agonist for treating Type II diabetes and also the first diabetes drug to get the agency's nod under the new cardiovascular safety guidelines adopted for diabetes drugs last year. (BioWorld Today) Read More
